Core Viewpoint - Baize Medical (02609) has seen a significant stock price increase of over 50%, reaching a new high of 17.06 HKD, with a cumulative rise of 130% over the past two trading days [1] Company Summary - As of the latest report, Baize Medical's stock price increased by 58.01%, trading at 16.19 HKD, with a trading volume of 1.437 billion HKD and a total market capitalization exceeding 20 billion HKD [1] - The company has been included in the Hong Kong Stock Connect list, effective from September 8, which has contributed to the increased trading activity [1] - Baize Medical operates in the "full-cycle cancer medical services" sector, providing services such as screening, diagnosis, treatment, and rehabilitation [1] - The company has successfully operated eight hospitals across five provinces and cities, including Beijing, Tianjin, Anhui, Shanxi, and Henan [1] - In the first half of the year, Baize Medical reported revenue of 575 million RMB, a year-on-year increase of 0.66%, while the loss attributable to shareholders widened to 27.62 million RMB, an increase of 139.18% year-on-year [1]
佰泽医疗再暴涨50%创新高 两个交易日股价飙升1.4倍 总市值突破200亿港元